Evidence map›Paper›PMID 34730684›Full record

ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2021

Rare type I CBFβ/MYH11 fusion transcript in primary acute myeloid leukemia with inv(16)(p13.1q22): a case report.

Wenyi Zhang, Hainan Wang, Peilei Zhang, Hongliang Li, Xiaoli Ma, Hongxing Liu

Open access · goldAbstract readCase Reports
In one paragraph

Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Genes · 2025
    Article
  3. The Fusion Genes and Their Relation with Genetic Variants in Egyptian AML Patients.Asian Pacific journal of cancer prevention : APJCP · 2025
    Article
  4. Article
  5. ConcurrentEJHaem · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Wenyi ZhangDepartment of Clinical Laboratory, Traditional Chinese Medical Hospital of Langfang City, Langfang, Hebei, China.ORCID http://orcid.org/0000-0001-8471-6396
Hainan WangDepartment of Medical Hematology, Traditional Chinese Medical Hospital of Langfang City, Langfang, Hebei, China.ORCID http://orcid.org/0000-0003-0471-4361
Peilei ZhangDepartment of Clinical Laboratory, Traditional Chinese Medical Hospital of Langfang City, Langfang, Hebei, China.ORCID http://orcid.org/0000-0001-7667-2127
Hongliang LiDepartment of Clinical Laboratory, Traditional Chinese Medical Hospital of Langfang City, Langfang, Hebei, China.ORCID http://orcid.org/0000-0002-1084-5651
Xiaoli MaDivision of Pathology and Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China.ORCID http://orcid.org/0000-0003-3465-3424
Hongxing LiuDivision of Pathology and Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China.ORCID http://orcid.org/0000-0002-0547-5721
Anyang Hospital of Traditional Chinese Medicine · CNHebei Yiling Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inv(16)(p13.1q22) in acute myeloid leukemia (AML) is a common chromosomal abnormality. It leads to the core-binding factor ß-subunit (CBFβ)/smooth muscle myosin heavy chain 11 (MYH11) fusion gene. Different breakpoints were observed in the CBFβ gene at 16q22 and the MYH11 gene at 16p13.1. For this reason, different CBFβ/MYH11 fusion genes are generated, with more than 13 types having been reported to date. Type I CBFβ/MYH11 fusion transcripts are very rare, with only 10 cases being reported to date. This case report describes a primary AML patient with inv(16)(p13.1q22) and a rare type I CBFβ/MYH11 fusion gene. The morphological analysis did not conform to the typical M4eo. Abnormal eosinophils were less than 5%, and there was obvious dysgranulopoiesis. The patient was in hematological and genetic remission for 487 days after the initial chemotherapy cycles. However, the CBFβ/MYH11 fusion had been constantly positive. Moreover, the presence of non-type A fusions may affect its biology and clinical prognosis. Therefore, further studies on understanding its biological and prognostic significance are essential.

Indexed as

Chromosome InversionLeukemia, Myeloid, AcuteHumansMyosin Heavy ChainsOncogene Proteins, FusionMYH11 protein, humanMyosin Heavy ChainsOncogene Proteins, Fusion

Identifiers

PMID34730684
PMCPMC8555453
OpenAlexW3205998733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.